An interventional study of Risk-based prediction models in Lung Cancer (Diagnosis) and COPD (Chronic Obstructive Pulmonary Disease), sponsored by Vejle Hospital. Recruiting at 1 site in Denmark. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Vejle Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.
Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 9th largest by planned enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2026, is one of 46 with no phase, reaches primary completion later than 29 of the 46 other live ones, and was the 124th registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:
Aarhus University Hospital · Sites in Denmark
Ages 18+
Vejle Hospital · Sites in Denmark
Ages 50+
Ditte Krag-Hansen · Sites in Denmark
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18+
Bristol-Myers Squibb · Sites in Denmark, United States, Argentina and 31 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 22 · Phase 3 16 · Phase 4 5
First in 1998; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 158 across the 94 interventional studies, 105 across the 30 observational. Of the 60 that completed or were terminated, 12 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 124 have an industry lead sponsor. The 10 most frequent:
Vejle Hospital is the lead sponsor of 95 studies on the registry; 13 are open to participants now.
Vejle Hospital has 7 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Lung Neoplasms with a site in Denmark that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06537804Odense University HospitalProject Lung Cancer Screening in Southern Denmark | 2026-12-31 |
| NCT05053997Zealand University HospitalNavigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients | 2026-12-31 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
Add all 12 to your calendar (.ics) → With an account.
Among the 124 studies in Lung Neoplasms with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the interventional study is to evaluate whether risk-based stratification using the PLCOm2012 model and a machine learning (ML) model can identify patients with chronic obstructive pulmonary disease (COPD) who are at high risk of developing lung cancer and may benefit from low-dose computed tomography (LDCT) screening. The study population includes adults aged 50 years and older with COPD and a history of smoking attending an outpatient clinic.
The main question it aims to answer are:
- What is the incidence of histopathologically confirmed lung cancer following risk-based stratification?
Participants will:
Lung cancer is a leading cause of cancer-related mortality in Denmark, largely due to late-stage diagnosis. Early detection through low-dose computed tomography (LDCT) has been shown to reduce mortality in trials such as the National Lung Screening Trial and the NELSON trial, but implementation remains limited due to cost, capacity, and risk of false-positive findings. Risk-based approaches may improve screening efficiency by identifying individuals at highest risk.
This prospective, single-centre interventional study evaluates the feasibility and clinical implementation of lung cancer risk stratification in patients with chronic obstructive pulmonary disease (COPD). A total of 1,000 patients will be enrolled from an outpatient clinic. At baseline, participants will undergo risk assessment using the PLCOm2012 model and a machine learning (ML)-based model based on clinical and laboratory data.
Patients identified as high-risk by either model will be referred for LDCT, while low-risk patients will continue standard care. If LDCT findings are suspicious, further diagnostic evaluation will be performed according to routine clinical practice. Participants will be followed through electronic health records for up to six years, with outcome assessment at 1, 2, and 6 years.
The primary outcome is the incidence of histopathologically confirmed lung cancer. Secondary outcomes include adherence to LDCT referral, time from risk assessment to LDCT, number needed to screen, healthcare utilization, healthcare costs, and safety, including adverse events related to diagnostic procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled patients with chronic obstructive pulmonary disease (COPD) will undergo lung cancer risk assessment using the PLCOm2012 model and an in-house developed machine learning model. Based on the model-derived risk score, patients will be stratified into high-risk and low-risk groups. Patients classified as high-risk will undergo further diagnostic evaluation for lung cancer according to the study protocol. Patients classified as low-risk will continue with standard of care management. Outcomes will be compared between risk groups to evaluate the feasibility and clinical utility of the model.
Other: Risk-based prediction models
Patients will be stratified into high-risk and low-risk groups using both the Lung Cancer Risk Prediction Calculator for smokers (PLCOm2012) and an in-house developed machine learning model based on sex, age, smoking status, and laboratory data from routine blood sample analyses.
Number of histopathologically confirmed lung cancers
Time frame: From risk assessment to end of follow-up at 6 years
Proportion of high-risk patients who undergo LDCT after referral
Time frame: From risk assessment to LDCT completion at 1 year
Number of COPD patients requiring risk assessment and LDCT screening to detect one case of lung cancer
Time frame: From risk assessment to end of follow-up at 6 years
Time from risk assessment to completion of LDCT
Time frame: From risk assessment to LDCT completion at 1 year
Number of diagnostic procedures per patient stratified by risk group
Time frame: From risk assessment to end of follow-up at 6 years
Number of hospitalizations per patient stratified by risk group
Time frame: From risk assessment to end of follow-up at 6 years
Number of outpatient visits per patient stratified by risk group
Time frame: From risk assessment to end of follow-up at 6 years
Healthcare costs per detected lung cancer case stratified by risk group
Time frame: From risk assessment to end of follow-up at 6 years
Healthcare costs per patient stratified by risk group
Time frame: From risk assessment to end of follow-up at 6 years
Proportion of eligible COPD patients consenting to risk assessment
Time frame: From risk assessment to end of follow-up at 6 years
Proportion of eligible COPD patients completing LDCT
Time frame: From risk assessment to LDCT completion at 1 year
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 865 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's planned 18 months is below that.
Counting every sponsor, half of 916 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vejle Hospital